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ABSTRACT 25 
8-Prenylnaringenin (8-PN) is a prenylflavonoid that originates from hop extracts and is thought 26 
to help prevent disuse muscle atrophy. We hypothesized that 8-PN affects muscle plasticity by 27 
promoting muscle recovery under disuse muscle atrophy. To test the promoting effect of 8-PN 28 
on muscle recovery, we administered an 8-PN mixed diet to mice that had been immobilized 29 
with a cast to one leg for 14 days. Intake of the 8-PN mixed diet accelerated recovery from 30 
muscle atrophy, and prevented reductions in Akt phosphorylation. Studies on cell cultures of 31 
mouse myotubes in vitro demonstrated that 8-PN activated the PI3K/Akt/P70S6K1 pathway at 32 
physiologic concentrations. A cell-culture study using an inhibitor of estrogen receptors and an 33 
in vivo experiment with ovariectomized mice suggested that the estrogenic activity of 8-PN 34 
contributed to recovery from disuse muscle atrophy through activation of an Akt 35 
phosphorylation pathway. These data strongly suggest that 8-PN is a naturally occurring 36 
compound that could be used as a nutritional supplement to aid recovery from disuse muscle 37 
atrophy.  38 
 39 
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INTRODUCTION 42 
Skeletal muscle comprises approximately 40% of the weight of the human body, and is crucial 43 
for locomotion, amino acid and glucose metabolism, heat generation, and bone homeostasis (7, 44 
21). Therefore, maintenance of muscle mass has a crucial role in human health.  45 
 46 
Muscle unloading because of immobilization, bedridden status, or space flight travel activates 47 
protein-degradation pathways such as the ubiquitin-proteasome system, and results in disuse 48 
muscle atrophy (DMA) (27, 35). When muscles are released from the conditions responsible for 49 
DMA, protein synthesis in skeletal muscle is promoted for recovery of the normal state.  50 
 51 
It has been demonstrated that insulin-like growth factor (IGF)-1 enhances phosphorylation of 52 
phosphatidylinositol-3 kinase (PI3K), which in turn leads to Akt phosphorylation (4, 34). 53 
Phosphorylated Akt represses nuclear translocation of the transcriptional factor forkhead box 54 
protein O (Foxo), which is responsible for induction of DMA-related genes such as atrogin-1 in 55 
the ubiquitin-proteasome system (36). Phosphorylated Akt also activates the kinase mechanistic 56 
target of rapamycin (mTOR), whose downstream targets, 70-kDa ribosomal protein S6 kinase 57 
(P70S6K) and eukaryotic inhibition factor 4E-binding protein (4E-BP1), have been shown to 58 
activate protein synthesis in skeletal muscle (2, 14). In addition, mTOR signaling is enhanced in 59 
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response to the protein kinases ERK1/2 and P90RSK (33, 48). Therefore, it is assumed that 60 
activation of these pathways is responsible for recovery from DMA through the promotion of 61 
protein synthesis in skeletal muscle (4, 11). In particular, Akt phosphorylation acts as a principal 62 
“switching regulator” in the balance between synthesis and degradation of proteins (4, 39). It 63 
has been demonstrated that Akt activation is responsible for muscle hypertrophy in transgenic 64 
mice in which active Akt is expressed inductively (19). Furthermore, muscle hypertrophy is 65 
correlated with phosphorylation of P70S6K1 or 4E-BP1 (2, 48). Exercise and/or amino acid 66 
supplementation can activate these signaling pathways to promote protein synthesis in skeletal 67 
muscle (12, 18, 28, 48).  68 
 69 
8-Prenylnaringenin (8-PN: Fig. 1) is one of the polyphenols found in Humulus lupulus L (hop) 70 
(41) and brewing products that use hop extracts. 8-PN is considered to be a “phytoestrogen” 71 
because it can bind to estrogen receptors (ERs) in a similar manner to soy isoflavones (32). 72 
Recently, we found that pre-feeding with 8-PN suppressed loss of muscle mass in denervated 73 
mice lacking locomotive activity (24). In that study, 8-PN accumulated in the gastrocnemius 74 
muscle (GM) at 2.66–6.44 nmol/g tissue, and caused inhibition of the protein 75 
degradation-inducing ubiquitin-proteasome system via Akt phosphorylation. Akt 76 
phosphorylation was also observed during protein synthesis, suggesting that 8-PN could 77 
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promote muscle recovery from DMA. However, no studies have shown that polyphenols, 78 
including 8-PN, can improve muscle recovery.  79 
 80 
In the present study, we aimed to assess the efficacy of 8-PN for recovery from DMA. Thus, 81 
supplementation with an 8-PN-containing diet was started from the recovery phase in mice 82 
already suffering from DMA (induced by cast immobilization of a hind limb). At the start of the 83 
recovery phase, the cast was removed for release from immobilization, and an 8-PN mixed diet 84 
was administered during the recovery phase. We also aimed to determine the effect of 8-PN on 85 
the protein-synthesis pathway in muscle tissue in vivo and in vitro in a muscle cell model 86 
(mouse C2C12 myotubes).  87 
 88 
 89 
 90 
 91 
 92 
 93 
 94 
 95 
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MATERIALS AND METHODS 96 
Ethical approval of the study protocol  97 
All experimental protocols were designed in accordance with the guidelines for the care and use 98 
of laboratory animals set by the Graduate School of the Institute of Biomedical Sciences, 99 
Tokushima University (Tokushima, Japan) and approved by the Committee on Animal 100 
Experiments of Tokushima University. To minimize animal suffering, surgery was undertaken 101 
under anesthesia using sodium pentobarbital.  102 
 103 
Materials 104 
8-PN was synthesized as described in our previous report (16), and its purity was >95%. 105 
Information about all other reagents used in this study is provided below. 106 
 107 
Animal experiment I: Estimation of loss and recovery of muscle weight by ankle fixation 108 
Seven-week-old male C57/BL6 mice (Japan SLC, Shizuoka, Japan) were housed in a room 109 
maintained at 23±1°C on a 12-h/12-h light/dark cycle. The mice had free access to a commercial 110 
diet (AIN-93M; Oriental Yeast Company, Tokyo, Japan) and water.  111 
 112 
The experimental schedule is shown in Fig. 1. We set an instrument designed to fix the ankle of 113 
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the right limb of each mouse at the dorsiflexion position in a tube (immobilized condition: 114 
“Im”). The tube was used as a cast. To prepare control muscles, the left hind limb remained free 115 
from the tube cast (normal condition: “Nom”). The duration of ankle immobilization was 14 116 
days.  117 
 118 
At day 14, the recovery period was started by removing the tube cast from the right ankle 119 
(reloading: “RL”) and the mice were placed under normal breeding conditions for 20 days (until 120 
day 34). Sacrifice was carried at day 14 and 34, and the GM and tibialis anterior muscle (TA) 121 
were collected. The extent of reduction in muscle mass was assessed by the ratio of the weight 122 
of atrophied muscle (cast side) to the weight of control muscle in each mouse. 123 
 124 
Experiment II: Effect of 8-PN on recovery from DMA 125 
Experiment II was performed using the same procedures for experiment I described above and 126 
shown in Fig. 1. Male C57/BL6 mice or female C57/BL6 mice at 2 weeks after ovariectomy 127 
were used. The tube cast was set to the right ankle of each mouse for 14 days. At day 14, the 128 
tube cast was released, and the mice were randomly separated into two groups of six. The mice 129 
were then supplied with the AIN-93M diet (control group) or an 8-PN (0.05% w/w: male mice; 130 
0.0005% or 0.00005% w/w: female mice) mixed AIN-93M diet (0.05%: PN group; 0.0005%: 131 
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H-PN group; 0.00005%: L-PN34 group). In the 8-PN mixed diet, the cellulose content was 132 
reduced to adjust the composition of the other nutrients. Pellets releasing 17β-estradiol (0.18 133 
mg/day) (SE-121; Innovative Research of America, Sarasota, FL, USA) were implanted 134 
subcutaneously into the estrogen group in ovariectomized mice. The TA weight was measured at 135 
the end of the feeding experiment (day 34). The level of recovery of muscle mass was 136 
calculated as the ratio of the weight of recovered muscle (cast side) to the weight of control 137 
muscle in each mouse. Samples of tissue and plasma were stored at −80°C until western blotting 138 
analysis (24). 139 
 140 
HPLC analyses 141 
HPLC analyses were carried out according to our previous report (24). Briefly, plasma (10 µL) 142 
was incubated with 100 U of β-glucuronidase type H-1 (possessing both β-glucuronidase 143 
activity and sulfatase activity) in 0.1 M sodium acetate buffer (pH 5.0; 90 µL) and 50 mM 144 
ascorbic acid (20 µL) for 45 min. 8-PN was extracted with ethyl acetate and evaporated using a 145 
centrifugal evaporator. The sample was injected into an HPLC–UV detection system 146 
(SPD-10AV; Shimadzu, Tokyo, Japan) equipped with a TSK-gel ODS-80Ts HPLC column (150 147 
× 4.6 mm; Tosoh, Tokyo, Japan) using a λmax value of 292 nm. In the mobile phase, solvent A 148 
was 0.5% phosphoric acid and solvent B was methanol containing 0.5% phosphoric acid. For 149 
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8-PN detection, solvent B was 65%. The flow rate was 1.0 mL/min. 150 
 151 
Cell culture and sample collection for western blotting analysis 152 
As described in our previous study (24), the mouse myoblast cell line C2C12 (American Type 153 
Culture Collection, Manassas, VA, USA) was obtained and its differentiation was initiated with 154 
2% horse serum-containing DMEM for 96 h. The differentiated cells were then desensitized 155 
with 0.1% BSA-containing DMEM for 16 h, exposed to 8-PN (0.1–10 µM) or vehicle (0.1% 156 
DMSO) for 0.25, 1, or 4 h, and washed with ice-cold HBSS. An ER inhibitor (fulvestrant; 157 
AdooQ BioScience, Irvine, CA, USA) at 50 µM was added to the cells at 10 min before PN 158 
treatment. The final concentration of DMSO in the medium was set at 0.1%. Cell lysates were 159 
collected with 100 µL of lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 160 
1% Triton X-100, protease inhibitor (Complete EDTA-free; Roche, Basel, Switzerland), 161 
phosphatase inhibitor (PhosSTOP; Roche)). The protein content of each lysate was measured by 162 
the Bradford assay (5). Samples were stored at −80°C until western blotting analysis. 163 
 164 
Western blotting 165 
Western blotting analyses were carried out as described in our previous study (24). Briefly, 166 
samples were separated by 10% SDS–PAGE, and transferred onto polyvinylidene difluoride 167 
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membranes (GE Healthcare, Piscataway, NJ, USA). The membranes were then incubated with 168 
commercial blocking buffer (Blocking-One P (for phosphorylated proteins) or Blocking-One 169 
(for other proteins); Nacalai Tesque, Kyoto, Japan) for 1 h to block non-specific binding. After 170 
detection of total protein by Ponceau S staining (0.1% w/w Ponceau S in 5% acetic acid aq.), the 171 
membranes were incubated for 1 h at room temperature with the following primary antibodies: 172 
anti-Akt (pan) (11E7) rabbit antibody, anti-PI3K antibody, anti-phospho-PI3K p85 (Tyr458)/p55 173 
(Tyr199) antibody, anti-phospho-P70S6K (Thr389) (1A5) mouse antibody, anti-GAPDH rabbit 174 
mAb, anti-pERK rabbit antibody, anti-ERK42/44 antibody, anti-p4E-BP1 Thr37/46 antibody, 175 
anti-p90RSK1 Thr359/Ser363 antibody (1:1000 dilution; Cell Signaling Technology, Danvers, 176 
MA, USA), anti-phospho-Akt (Ser473) (193H12) rabbit mAb, anti-P90RSK1/2/3 antibody 177 
(1:500 dilution; Cell Signaling Technology), or anti-P70S6K1 antibody (1:1000 dilution; Santa 178 
Cruz Biotechnology, Santa Cruz, CA, USA). After washing with TBS containing 0.05% 179 
Tween-20 (TBST), the membranes were incubated with peroxidase-labeled secondary 180 
antibodies for 1 h. After three washes with TBST, the immunocomplexes were visualized with a 181 
chemiluminescence detection kit (ECL prime; GE Healthcare) and analyzed using ImageJ 182 
software (National Institutes of Health, Bethesda, MD, USA). Phosphorylated proteins (except 183 
for 4E-BP1) were normalized by the total amount of each protein.  184 
 185 
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Statistical analyses 186 
Data are shown as means ± SE. The data shown in Figs. 3C, 3D, 5, and 6 were analyzed by 187 
one-way ANOVA with the Tukey multiple comparison test (P < 0.05). The data shown in Figs. 2, 188 
3B, and 4 were analyzed by a two-sided Student’s t-test (P < 0.05). 189 
 190 
RESULTS 191 
Change in muscle mass in mice with fixation of the right ankle at maximum dorsiflexion 192 
To observe the recovery of muscle mass from immobilization, we developed a new model of 193 
DMA by fixing the right ankle at maximum dorsiflexion in a tube cast. The TA of the leg 194 
immobilized with the tube cast for 14 days decreased in weight to 66.7% of the initial weight, 195 
while the mass of the GM was maintained at 103% (Fig. 2). Over a period of 20 days after 196 
reloading (34 days from start of fixation), the weight of the TA increased significantly to reach 197 
82.8% of the initial weight (P = 0.026). Therefore, we confirmed that our newly developed 198 
method was suitable for estimating recovery of muscle mass from DMA. 199 
 200 
Promotion of recovery of muscle weight after DMA by intake of an 8-PN mixed diet 201 
To estimate the effect of 8-PN on the recovery from DMA induced by cast immobilization, an 202 
8-PN mixed diet was administered to mice during the period of reloading (from release of 203 
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immobilization at day 14). Food intake during the entire experiment and body weight at the 204 
final point of dissection did not vary between the control group and the 8-PN mixed-diet group 205 
(Fig. 3A, B). At 20 days after reloading (day 34), the control group (RL-C) and 8-PN group 206 
(RL-PN) had recovered from DMA. The 8-PN mixed-diet group showed significantly higher 207 
muscle weight than the control group (Fig. 3C; ANOVA P = 4.58 × 10−9), suggesting that 8-PN 208 
promoted muscle recovery after release from immobilization by the tube cast. The plasma IGF-1 209 
concentration in the PN group at day 34 was significantly higher than that in the control group 210 
(Fig. 3D; ANOVA P = 9.68 × 10−11).  211 
 212 
Effect of 8-PN on a protein synthesis-related pathway in the TA 213 
Among the signaling pathways responsible for muscle synthesis upon 8-PN intake, we first 214 
detected changes in Akt phosphorylation (Fig. 4). At day 14, immobilization significantly 215 
attenuated Akt phosphorylation (P = 0.004). At day 34, higher Akt phosphorylation was 216 
observed in the normal leg (Nom-C: without immobilization with the control diet for 34 days), 217 
while the reloaded leg (RL-C: 14 days of immobilization and 20 days of reloading with the 218 
control diet) showed significantly lower phosphorylation of Akt (P = 0.032). In contrast, no 219 
reduction in Akt phosphorylation was observed in the PN group. RL-C (P = 0.045) and RL-PN 220 
(P = 0.012) showed higher Akt phosphorylation compared with Im-C. Phosphorylation of 221 
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mTOR (p-mTOR) in RL-C was significantly higher than that in Im-C (P = 0.019). 222 
Phosphorylation of mTOR was also increased in RL-PN compared with Im-C, but a significant 223 
difference was not found. In addition, the level of p4E-BP1 was increased in RL-PN compared 224 
with Im-C. P70S6K1 in RL-PN showed slightly higher phosphorylation compared with Im-C 225 
(Fig. 4). These data suggested that immobilization attenuated signaling pathways that included 226 
phosphorylation of Akt and 4E-BP1. Phosphorylation of mTOR and P70S6K1 was increased in 227 
the recovery phase, and 8-PN accelerated muscle recovery by changing the phosphorylation of 228 
Akt, 4E-BP1, mTOR, and P70S6K1 during reloading. No changes were observed in total 229 
protein between the interventions (data not shown). Among the above four targets, pAkt and 230 
pP70S6K showed different trends compared with the control diet (at day 34), although the 231 
results of this animal experiment could not explain the effects of 8-PN on the phosphorylation 232 
of these proteins in vivo. Thus, we carried out additional cell-culture experiments to clarify the 233 
influence of 8-PN on the phosphorylation of the proteins responsible for muscle recovery. 234 
 235 
Activation of the PI3K/Akt signaling pathway by 8-PN in mouse myotubes 236 
The plasma 8-PN concentrations in 8-PN-fed mice were determined to ascertain the 8-PN 237 
concentration applied for the experiments on C2C12 myotubes. The concentrations were found 238 
to be 1.19 ± 0.18 µM at day 34 in the 8-PN-fed mice. We detected changes in phosphorylation 239 
15 
 
of Akt, P70S6K1, and PI3K in C2C12 myotubes. 8-PN increased Akt phosphorylation without 240 
changing the total level of Akt (non-phosphorylated and phosphorylated Akt) in C2C12 241 
myotubes (Fig. 5). Treatment with 8-PN for 1 h elicited significant activation of Akt 242 
phosphorylation (ANOVA P = 0.003). Phosphorylation of PI3K, Akt, and P70S6K1 was 243 
increased upon 8-PN treatment without changes in the total amounts of these proteins, or those 244 
of GAPDH (Fig. 6). 8-PN (0.1 or 1 µM) activated PI3K phosphorylation, while P70S6K1 (0.1 245 
or 1 µM) and 8-PN (1 or 10 µM) increased Akt phosphorylation. 246 
 247 
Involvement of estrogenic activity in the contribution of 8-PN to recovery of muscle mass  248 
Fulvestrant is an ER inhibitor. Fulvestrant suppressed 8-PN-induced phosphorylation of Akt and 249 
P70S6K1 in C2C12 cells (Fig. 7). In ovariectomized mice, 8-PN promoted recovery of muscle 250 
mass in the H-PN34 group (0.0005% 8-PN group at day34) in comparison with the C34 group 251 
(control-diet group at day34) (Fig. 8). Administration of 17β-estradiol also enhanced recovery 252 
of muscle mass, because the muscle mass in the E34 group (Estrogen tablet group at day 34) 253 
was significantly higher than that in the C34 group. Therefore, it is likely that the estrogenic 254 
activity of 8-PN is involved in its promotion of recovery of muscle mass from an atrophied 255 
condition. 256 
 257 
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DISCUSSION 258 
Muscle atrophy is caused by immobilization, space flight, or aging. Food components that can 259 
promote muscle recovery are undoubtedly helpful for human health. The present study 260 
demonstrated that 8-PN derived from foods and beverages can promote recovery of muscle 261 
mass after DMA.  262 
 263 
We developed an appropriate model to estimate muscle recovery. Experiments involving 264 
suspension or denervation of rodent tails have generally been used as models of DMA. However, 265 
access to a diet and water during tail suspension is difficult, and neurologic disorders can occur 266 
in denervated animals. These conditions hinder estimations of the effects of diet or drugs on 267 
DMA. In humans, immobilization with a cast can reflect the realities of DMA, but it is difficult 268 
to create the same extent of fixation throughout experiments. The method developed in the 269 
present study can be used to estimate how an agent promotes protein synthesis under DMA in 270 
mice. We fixed the right ankle of each mouse at maximum dorsiflexion with a tube, which acted 271 
as a cast. This technology is currently awaiting a patent (number #2015-074324). The region of 272 
atrophied muscle is dependent on the position and degree of flexion (9). We fixed the ankle of 273 
the mice at maximum dorsiflexion in the tube cast. This position of fixation induced muscle loss 274 
not in the posterior region of the leg (GM), but in the anterior region of the leg (TA). Normal 275 
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mobilization (a fundamental physical condition for protein synthesis) of the hind limb was 276 
observed at 2 days after reloading. The mass of the TA of the atrophied leg was increased at 20 277 
days after reloading (Fig. 2), suggesting the promotion of protein synthesis upon physical 278 
activity. Our method for targeting promotion of the recovery of muscle mass by release of 279 
cast-based immobilization appears able to accurately reflect human rehabilitation after cast 280 
immobilization, bed rest, or space flight. Therefore, this model can be suitable for estimating 281 
muscle recovery after atrophy. It should be noted that the phosphorylation of mTOR, ERK, and 282 
P70S6K1 in Nom-C at 34 days was unexpectedly higher than that in Nom-C at 14 days. The leg 283 
without a cast at 34 days would be affected by mobilization signals occurring in RL-C, because 284 
the exercise (mobilization) condition affects the protein synthesis pathway through the secretion 285 
of hormonal factors (8, 30). However, comparisons between a leg with a cast and a leg without a 286 
cast in the same body can avoid the influences of nutrient intake, and this model therefore 287 
appears suitable for estimating the effect of 8-PN on muscle recovery from DMA. 288 
 289 
Epigallocatechin gallate and resveratrol applied to tail-suspended mice have been shown to 290 
regulate muscle mass by suppressing an apoptotic pathway and activating the proliferation of 291 
satellite cells (1, 3). In those studies, epigallocatechin gallate and resveratrol affected the 292 
degradation and synthesis of muscle because supplementation was started at the initial point of 293 
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suspension (1, 3). Indeed, it has also been demonstrated that these polyphenols downregulate 294 
the protein-degradation pathway during the development of muscle atrophy (13, 46, 47). Here, 295 
we focused on the specific effect of 8-PN on muscle during the recovery phase. 8-PN 296 
supplementation was started at the beginning of the recovery (reloading) period. This is the first 297 
report showing that a natural polyphenol can elicit muscle recovery after DMA onset. The total 298 
intake of the diet was identical among the groups (Fig. 3A), meaning that no nutrients other than 299 
8-PN affected the muscle recovery differently between the control-diet group and the 8-PN 300 
group. The plasma concentration of 8-PN reached >1 µM in our study, and muscular 301 
accumulation of 8-PN at 2.66–6.44 nmol/g tissue was observed in our previous study (24). 302 
Intake of an 8-PN diet during the recovery period appeared to enable accumulation of 8-PN in 303 
the TA, and revealed a promotive effect. 8-PN “lodges” in myotubes through its prenyl-group, 304 
and is not excreted from myotubes via ATP-binding cassette transporters (24). Prenylated 305 
quercetin also accumulates in tissue (including skeletal muscle) after its continuous intake (23, 306 
42). Thus, prenylation of flavonoids is advantageous for accumulation in skeletal muscle. In 307 
addition, greater amounts of 8-PN compared with non-prenylated molecules were found to 308 
accumulate in skeletal muscle in vivo and activate Akt phosphorylation (24). The major 309 
polyphenol catechin can activate PI3K phosphorylation in myotubes, and its effect is enhanced 310 
by acylation (43). These observations may suggest that modification of polyphenols by a 311 
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hydrophobic functional group (e.g., prenylation) can enhance their biologic effects in skeletal 312 
muscle. 313 
 314 
8-PN promoted recovery of muscle mass even though the food intake and weight increase were 315 
identical between the 8-PN-diet group and the control-diet group (Fig. 3). Thus, the 316 
phenomenon induced by 8-PN was not derived from the balance of nutrient intake and/or 317 
expenditure of total energy, but instead arose through changes in the synthesis and/or 318 
breakdown of muscle. IGF-1 secretion was activated by 8-PN (Fig. 3), although IGF-1 signaling 319 
was lost during DMA because unloading stress triggers IRS-1 degradation (26). Therefore, 8-PN 320 
exerted its effect on skeletal muscle directly. pAkt, pmTOR, pP70S6K1, and p4E-BP1 were 321 
increased in the RL-C muscle (Fig. 4). These phosphorylations are activated by exercise (10, 322 
22), meaning that reloading trigged this signaling pathway. In the 8-PN group, these proteins 323 
were also activated during reloading, but their activation was similar to that in the control-diet 324 
group. Amino acids such as leucine activate protein-signaling pathways to synthesize proteins in 325 
normal muscle (17), while 8-PN (or other polyphenols) that suppress muscle atrophy do not 326 
increase muscle mass under normal conditions (24, 25). Ascertaining the additional effect of 327 
8-PN on normal mobility (reloading) when the TA has almost reached a plateau in its normal 328 
muscle mass would be difficult. In contrast, 8-PN enhances Akt phosphorylation in acutely 329 
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atrophied muscle (24). These findings imply that 8-PN could accelerate these signaling 330 
pathways during recovery at an early stage. The Akt phosphorylation pathway plays an 331 
important part in protein synthesis during recovery from DMA (4, 39). A reduction in the level 332 
of Akt phosphorylation in the TA with a cast led to acceleration of protein degradation by 333 
immobilization (Fig. 4). Akt phosphorylation was relatively stable in the 8-PN group at day 34 334 
because the TA had almost reached a plateau of protein synthesis. The extent of Akt 335 
phosphorylation in this group was sufficient to maintain the muscle mass because the level was 336 
similar to that in Nom-C at day 14. P70S6K1 phosphorylation is significantly correlated with 337 
muscle recovery from atrophy (6). The phosphorylation status of P70S6K1 in the 8-PN group 338 
tended to be different from that in the control group. This phosphorylation state was responsible, 339 
at least partly, for the protein synthesis in the RL-PN group. The phosphorylation detected in 340 
our study could not have occurred simultaneously. Time-course experiments are required to 341 
assess the time-dependent changes in the phosphorylation of each signaling molecule.  342 
 343 
To estimate the effect of 8-PN at physiologic concentrations, we first measured the mean plasma 344 
concentration in test mice and determined it to be 1.19 µM. Rad et al. (29) showed that 8-PN 345 
circulates at ≤0.1 µM in human plasma after single ingestion of 8-PN at 750 mg. A plasma 346 
concentration of >1 µM 8-PN was detected at 24 h after a single ingestion of 8-PN in a rodent 347 
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study (24). That rodent study suggested that the presence of an active aglycone, together with its 348 
conjugated metabolites, in the circulation after oral ingestion of 8-PN (24). Thus, we applied an 349 
aglycone of 8-PN (0.1–10 µM) to cultured cells. 8-PN at these concentrations was able to 350 
activate PI3K/Akt/P70S6K1 phosphorylation within 1 h (Fig. 6). The maximum cellular 351 
accumulation of 8-PN in C2C12 cells was accomplished within 1 h, and its accumulation was 352 
maintained until 24 h (24). These data suggest that 8-PN accumulated in muscle cells activates a 353 
pPI3K/Akt/P70S6K1 pathway. Promotion of a protein-synthesis signaling pathway involving 354 
phosphorylation of Akt followed by phosphorylation of P70S6K1 is activated by amino-acid 355 
supplementation and/or resistance exercise (15, 24, 37). 8-PN may boost the promoting effects 356 
of nutrients and exercise on protein synthesis in skeletal muscle.  357 
 358 
8-PN is a phytoestrogen in vitro and in vivo (29, 32). In ovariectomized rats, 8-PN was shown to 359 
have similar effects to estradiol (31). It has been reported that estrogen can affect the 360 
maintenance of skeletal muscle regardless of sex (38, 40). ERβ activation leads to the growth 361 
and regeneration of muscle (45), and 8-PN can bind to ERβ (32). 17β-estradiol activates 362 
PI3K/Akt phosphorylation via ERs in murine myotubes (44), and increases the number of 363 
satellite cells in muscle after exercise via PI3K phosphorylation (but not IGF-1 secretion) (20). 364 
Fulvestrant diminished the effects of 8-PN (i.e., enhancement of Akt and P70S6K1 365 
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phosphorylation (Fig. 7)). In addition, the increased muscle mass after 8-PN consumption was 366 
reproduced by administration of 17β-estradiol (Fig. 8). Thus, PI3K phosphorylation is possibly 367 
triggered by binding of 8-PN to ERβ. The mechanism of action for 8-PN-dependent acceleration 368 
of muscle recovery from DMA may be related to its estrogenic activity. 369 
 370 
Our data confirmed that 8-PN accelerates muscle recovery after DMA onset. Furthermore, 8-PN 371 
was found to activate the phosphorylation of Akt, 4E-BP1, and P70S6K1 during reloading in 372 
mice. At physiologic concentrations, 8-PN activated the phosphorylation of PI3K, Akt, and 373 
P70S6K1 in myotube cells, and this 8-PN-dependent activation of phosphorylation seemed to be 374 
associated with its estrogenic activity. As basic nutritional supplementation and exercise are 375 
critical for muscle recovery, taking 8-PN as a supplement could enhance the effects of these 376 
factors during rehabilitation after DMA. The effect of 8-PN on muscle recovery could provide 377 
reference information for developing supplements supporting muscle maintenance. 378 
 379 
Perspectives and Significance 380 
This is the first study to demonstrate the promoting effect of a dietary flavonoid on recovery 381 
from disuse muscle atrophy in rodents. A cure for atrophy of skeletal muscle can help toward 382 
improvement of quality of life by suppression of metabolic disorders. The effect is different 383 
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from that of glucocorticoids (which strengthen anabolism of skeletal muscle), because the 384 
8-prenylnaringenin (8-PN) used in this study only exerted a promoting effect under the 385 
atrophied condition. The present study provides: (i) basic information on the development of 386 
nutritional therapy by flavonoids; and (ii) a candidate that can boost the effect of rehabilitation 387 
of skeletal muscle. Flavonoids other than 8-PN that possess estrogenic activity may also exert a 388 
similar effect, because the promoting effect of 8-PN appeared to be associated with its 389 
estrogenic activity. 8-PN is a prenylated flavonoid. Prenylation may improve the effect of 390 
natural products (including flavonoids) under development for the treatment of muscle atrophy. 391 
Demonstration of a synergistic effect between 8-PN supplementation and exercise or amino-acid 392 
supplementation is crucial to establish utility in clinical practice. 393 
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 552 
Figure legends 553 
 554 
Figure 1. (A) Structure of 8-PN. (B) Experimental schedule: day 0 to day 14 was the 555 
atrophy-development period; day 14 to day 34 was the recovery period. To induce atrophy, the 556 
right hind leg of each mouse was immobilized with a tube cast, and the left hind leg remained 557 
free from the tube cast. At day 14, the tube cast was removed from the right leg. At day 14 and 558 
day 34, muscles were collected to estimate the level of atrophy. 559 
 560 
Figure 2. Muscle atrophy and recovery from DMA in the right hind leg of mice. DMA was 561 
induced by immobilization using a tube cast (see Fig. 1). The muscle masses after 14 days of 562 
immobilization (Im) and 20 days of reloading (RL) are shown in the GM (A) and TA (B). These 563 
levels were calculated using the ratio of atrophied muscle (with cast) to normal muscle (without 564 
cast). Data are means ± SE (n = 4). *P < 0.05, significant difference compared with Im. 565 
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 566 
Figure 3. Effect of intake of an 8-PN mixed diet on recovery of muscle mass from DMA. The 567 
immobilization with the cast lasted for 14 days, and the mice were then released from the cast. 568 
Recovery was estimated at day 34. (A) Mean intake of food per day in all experiments. (B) 569 
Body weight at the end of the experiment (day 34). (C) Muscle mass in the TA. These levels 570 
were calculated using the ratio of atrophied muscle (with cast) to normal muscle (without cast). 571 
(D) Plasma concentration of IGF-1. Im-C: at day 14; RL-C: at day 34 (after recovery from 572 
immobilization) with the control diet; RL-PN: at day 34 (after recovery from immobilization) 573 
with the 8-PN mixed diet. Different letters represent significant differences (P < 0.05) by 574 
one-way ANOVA with the Tukey multiple comparison test.  575 
 576 
Figure 4. Effect of an 8-PN mixed diet on a protein-synthesis pathway in the TA. The 577 
phosphorylation of target proteins was evaluated by western blotting. (A) Typical images of 578 
western blotting. (B) Density analysis for the phosphorylation level within each total protein. 579 
Data are means ± SE. *P < 0.05, significant difference between Nom and another group. †P < 580 
0.05, significant difference between Im-C and RL. Nom: without tube cast; Im: with tube cast; 581 
RL: reloading; C: control diet; PN: 8-PN diet. 582 
 583 
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Figure 5. Enhancement of Akt phosphorylation by 8-PN in C2C12 myotubes. Murine C2C12 584 
myotubes were treated with 8-PN (1 µM) for 0.25–4 h. Phosphorylated Akt was determined by 585 
western blotting. (A) Typical images of western blotting. (B) Band densities for phosphorylated 586 
Akt. Data are means ± SE (n = 3). Different letters represent significant differences (P < 0.05) 587 
by ANOVA with the Tukey multiple comparison test. 588 
 589 
Figure 6. Effects of 8-PN on phosphorylation of PI3K, Akt, and P70S6K1 in murine C2C12 590 
myotubes. (A) Typical images of western blotting. (B–D) Band densities for phosphorylated 591 
PI3K (B), phosphorylated Akt (C), and phosphorylated P70S6K1 (D). Data are means ± SE (n = 592 
3). Different letters represent significant differences (P < 0.05) by ANOVA with the Tukey 593 
multiple comparison test. 594 
 595 
Figure 7. Contribution of estrogenic activity of 8-PN to Akt/P70S6K phosphorylation. Murine 596 
C2C12 myotubes were treated with 8-PN (1 µM) for 1 h in the presence of an ER inhibitor 597 
(fulvestrant). (A) Typical images of western blotting. (B) Band densities for phosphorylated 598 
proteins. Data are means ± SE (n = 3). Different letters represent significant differences (P < 599 
0.05) by ANOVA with the Tukey multiple comparison test.  600 
 601 
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Figure 8. Effects of ovariectomy and estradiol supplementation on muscle mass of atrophied 602 
mice. An 8-PN (0.0005% w/w: H-PN group; 0.00005% w/w: L-PN group) mixed diet or pellets 603 
releasing 17β-estradiol (E) were supplied to mice. The muscle mass in the TA was calculated 604 
using the ratio of atrophied muscle (with cast) to normal muscle (without cast). Different letters 605 
represent significant differences (P < 0.05) by ANOVA with the Tukey multiple comparison 606 
test. 607 
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